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Summary
Background: Immunosuppressive agents are being investigated for the treatment of 
chronic	kidney	disease	(CKD)	but	may	increase	risk	of	infection.	This	was	a	retrospec-
tive	 observational	 study	 intended	 to	 evaluate	 the	 risk	 of	 hospitalized	 infection	 in	









had type 2 diabetes.	In	these	latter	patients,	the	adjusted	hazard	ratios	(aHR)	were	













vourable	 risk-	benefit	 ratio	 (G1-	G3a	 in	 type	2	diabetes;	G1-	G2	 in	 nondiabetes	 and	
overall	cohorts)	although	the	degree	of	proteinuria	needs	to	be	considered.








gression of nephropathy by maintaining good metabolic and hemo-
dynamic control. Glycemic control is an important factor in reducing 
the	 microvascular	 complications	 that	 lead	 to	 nephropathy:	 the	 UK	
Prospective	 Diabetes	 Study	 (UKPDS)	 showed	 that	 diabetic	 patients	
receiving	 glucose-	lowering	 treatment	 who	 achieved	 good	 glycemic	
control	were	less	likely	to	progress	to	end-	stage	renal	disease	(ESRD).4 
Antihypertensives	 such	 as	 angiotensin-	converting-	enzyme	 (ACE)	
inhibitors	 and	 angiotensin	 receptor	 blockers	 (ARBs)	 also	 play	 a	 role	
in	 slowing	 the	progression	of	 kidney	disease	by	 inhibiting	 the	 renin-	
angiotensin-	aldosterone	system.	The	ADVANCE	trial	reported	reduced	
onset of microalbuminuria and no progression to nephropathy from 
existing	microalbuminuria	in	patients	with	type	2	diabetes	treated	with	




and immune activation play an important role in the progression of 





complication	 of	 kidney	 disease13,14	 and,	 separately,	 of	 diabetes.15 
Therefore,	a	careful	evaluation	of	the	risk-	benefit	profile	of	using	such	
therapies in patients with diabetic nephropathy is warranted.
Currently,	there	are	limited	data	available	describing	the	true	in-
cidence of infections in the diabetic nephropathy population specifi-
cally,	and	how	this	varies	by	CKD	stage	and	the	degree	of	proteinuria.	
McDonald et al16 demonstrated an association between decreased 





fection	 in	adult	patients	with	CKD	 in	 type	2	diabetes,	with	similar	
data for those with nondiabetes and type 1 diabetes for complete-
ness,	 in	order	 to	determine	how	severe	 infections	varied	by	eGFR	
stage	and	severity	of	proteinuria.	Furthermore,	we	aimed	to	identify	
where	infection	risk	was	lowest,	in	order	to	identify	the	most	appro-
priate stage in which to intervene with immunosuppressants.
2  | METHODS
2.1 | Study design and data sources
Data	 for	 this	 retrospective	 cohort	 study	 were	 from	 the	 UK	 





representing	 7%	 of	 practices	 in	 the	 UK	 National	 Health	 Service	




ring the patient to secondary care as necessary.
At	July	2015,	CPRD	contained	data	from	more	than	13	million	
research-	quality	 patients.	 Recorded	 data	 include	 demographics,	
clinical	 symptoms	 and	 diagnoses,	 tests	 ordered	 in	 primary	 care,	
assessments	(such	as	blood	pressure,	body	mass	index),	prescrip-
tions	 and	 referrals	 to	 secondary	 care.	 For	 approximately	50%	of	
patients	 in	 CPRD,	 linked	 secondary-	care	 data	 are	 available	 from	










Patients	 were	 included	 if	 their	 patient-	level	 information	 and	
practice-	recording	systems	were	classed	as	being	of	acceptable	re-
search	quality	by	CPRD.	Patients	were	also	 required	 to	be	eligible	
to	have	 their	 records	 linked	 to	 the	HES	data	 set.	The	observation	
period	began	in	1997	and	ended	in	2014.	The	following	patient	se-




•	 Registration	 at	 the	practice	 for	365	days	or	more	 at	 index	date	
(defined	as	the	earlier	of	the	patient’s	first	positive	eGFR	or	pro-
teinuria	test).	Positive	proteinuria	tests	that	were	on	the	same	day	
or had the same consultation identifier as a record of urinary tract 
infection	were	excluded.
K E Y W O R D S
albuminuria,	chronic	kidney	disease,	eGFR,	infection
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•	 Aged	40	years	 or	 older	 at	 index	date	 (25	years	 or	 older	 for	 pa-
tients	with	type	1	diabetes)
•	 No	prior	dialysis,	kidney	transplant,	or	cancer	at	index	date.
Patients	were	grouped	 in	 the	 following	cohorts:	 type	1	diabetes	
(T1DM),	 type	2	diabetes	 (T2DM)	or	no	diabetes	 (non-	DM)	based	on	
their	history	prior	to	index	date.









(a term that may be misapplied to patients with type 2 diabetes 
receiving	insulin	therapy)
•	 At	 least	 one	diagnosis	 of	 type	1	diabetes	 and	 aged	30	years	or	
younger at diabetes presentation (earlier of first insulin or first 
diagnosis)
Members	 of	 the	 type	 2	 diabetes	 (T2DM)	 cohort	 were	 required	
to	be	aged	40	years	or	older	at	 index	date	and	 to	have	a	diagnostic	










tes	or	glucose-	lowering	 therapy	 in	 the	data	 source	and	 to	have	no	







went renal replacement therapy or died during the study period.
2.3 | Study end- points
For	all	cohorts,	the	study	end-	points	were:




•	 Adjusted	 risk	 of	 first	 admission	 for	 infection	 by	 eGFR	 category	
and proteinuria level
Glomerular filtration rate values were estimated from serum 
creatinine	 test	 results	 by	 means	 of	 the	 CKD	 Epidemiology	
Collaboration	 (CKD-	EPI)	 equation,21 incorporating its adjustment 
for	 black	 ethnicity	 where	 this	 could	 be	 identified	 from	 CPRD	 or	
HES	data.









To address the challenge of identifying specific measures 
of proteinuria with appropriate units of measurement from the 
three	 quantitative	 entities,	we	 extended	 the	 approach	 of	 Liang	
et al22	 by	 classifying	 each	 test	 entity,	 unit	 of	measurement	 and	
accompanying	 Read	 code	 as	 specific,	 nonspecific,	 or	 conflict-
ing	 with	 	respect	 to	 each	 of	 these	 measures	 in	 turn:	 albumin-	
creatinine	ratio,	protein-	creatinine	ratio,	albumin	excretion	rate,	
protein	 excretion	 rate,	 spot	 albumin	 and	 spot	 protein.	 Records	




flicting	 (albumin-	creatinine	 ratio)	 but	 the	 unit	 of	 measurement	
was specific.
Qualitative	results	were	identified	from	the	qualitative	test	en-












The	 eGFR	 and	 proteinuria	 data	 were	 derived	 from	 CPRD	 and	
HES	 records.	 In	 accordance	 with	 the	 Kidney	 Disease:	 Improving	
Global	Outcomes	(KDIGO)	clinical	practice	guidelines,23 the sever-
ity	of	CKD	was	graded	into	six	categories,	from	G1:	normal	or	high	
to	G5:	 kidney	 failure,	 based	 on	 the	 patient’s	 eGFR	measurements	
(Table	S1).	Classification	of	proteinuria	 severity	was	also	based	on	
a	KDIGO	classification,	from	A1:	normal	to	mildly	increased	to	A3:	
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diastolic	 blood	 pressure,	 creatinine	 and—for	 the	 diabetes	 co-
horts—HbA1c	 were	 identified	 from	 the	 nearest	 record	 to	 index	
date,	provided	this	was	no	more	than	365	days	before	or	30	days	
after	 index	 date	 and	 searching	 in	 the	 following	 order:	 −30	days,	







hospital with a primary diagnosis of infection were calculated per 
1000	patient	years’	(pkpy)	follow-	up.





for	 eGFR	 category	 (reference	 G2,	 “mildly	 decreased”)	 and	 pro-
teinuria	level	(reference	A1,	“normal	to	mildly	increased”)	 in	quar-
terly	 updated	 time-	dependent	 models.	 Where	 appropriate,	 the	
models	were	 adjusted	 for	 age,	 gender,	 baseline	 body	mass	 index	
(BMI),	baseline	blood	pressure,	glycosylated	haemoglobin	(HbA1c),	
smoking	 status,	diabetes	 cohort,	 index	year	 and	prior	 comorbidi-
ties	(coronary	heart	disease	[CHD],	congestive	heart	failure	[CHF],	
hypertension	 cerebrovascular	 disease,	 dementia,	 other	 neurolog-
ical	 disorders,	 chronic	 obstructive	 pulmonary	 disease	 [COPD],	
chronic	 liver	disease	and	any	antihypertensives	 [ACE/ARB]	 in	the	
year	prior).	The	eGFR	level	G2	was	chosen	as	the	referent	because	
there	were	 small	 numbers	of	 patients	with	 an	eGFR	of	G1	 (“nor-
mal	or	high”)	at	index	date.	These	analyses	were	carried	out	using	




A	 total	 of	 97	839	patients	with	CKD	 fulfilled	 the	 selection	 crite-
ria,	 comprising	85	934	patients	 in	 the	 non-	DM	cohort,	 11	719	 in	
the	T2DM	cohort	and	186	 in	 the	T1DM	cohort.	Baseline	charac-













3.2 | Crude hospitalization rates for infection
Rates of hospital admission for infection were higher in the T2DM 
cohort,	 at	 33.3	 admissions	 per	 1000	 patient	 years	 (pkpy),	 than	
in	 the	 non-	DM	 cohort	 (24.9	 admissions	 pkpy)	 and	 T1DM	 cohort	
(24.0	 pkpy,	 P	<	0.001,	 Table	2).	 Examining	 admissions	 by	 infec-
tion	 type,	 hospitalization	 rates	 in	 the	 T2DM	 cohort	 were	 higher	
than	 in	 the	 non-	DM	 cohort	 for	 genitourinary	 infection	 (10.5	 vs	
7.3	pkpy,	P	<	0.001,	respectively),	pulmonary	 infection	(7.8	vs	6.6	
pkpy,	 P	<	0.001,),	 skin	 and	 soft	 tissue	 infection	 (5.9	 vs	 2.9	 pkpy,	
P	<	0.001,),	sepsis	(1.5	vs	0.9	pkpy,	P	<	0.001,)	and	bone	and	joint	
infection	 (1.2	vs	0.2	pkpy,	P	<	0.001,).	Patients	with	T1DM	had	a	
higher	 rate	 of	 skin	 and	 soft	 tissue	 infection	 (11.6	 pkpy)	 than	 did	
patients	 in	 the	 T2DM	 (5.9	 pkpy)	 and	 non-	DM	 cohorts	 (2.9	 pkpy,	
P	<	0.001	Table	2).
3.3 | Unadjusted risk of progression to 
hospital admission




and	G5	 (Figure	1B);	 these	were	16.8	years	 in	G3a,	15.0	years	 in	
G3b	 and	 6.5	years	 in	 G5,	 respectively.	 Patients	with	 a	 protein-









bined cohort patients had no diabetes.
3.4 | Adjusted risk of progression to 
hospital admission
Adjusting	 for	 age,	 gender,	 baseline	 BMI,	 baseline	 blood	 pressure,	
HbA1c,	 smoking	 status,	 diabetes	 cohort,	 index	 year	 and	 prior	 co-
morbidities	and	examining	all	CKD	patients	together,	we	found	no	
difference	 in	 infection	 rates	 between	patients	 in	 eGFR	 categories	
G1	 and	 the	 referent	 category	G2	 (aHR	=	1.03,	 95%	CI:	 0.90-	1.17).	
However,	in	the	G3a	category	the	aHR	was	1.18	(1.13-	1.23),	in	G3b,	
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1.57	(1.49-	1.65),	in	G4,	2.28	(2.12-	2.44)	and	in	G5,	3.74	(3.16-	4.42).	
Risks	of	infection	were	higher	in	proteinuria	levels	A2	(aHR	=	1.35,	
1.26-	1.44),	A23	 (aHR	=	1.28,	 1.13-	1.44)	 and	A3	 (aHR	=	1.74,	 1.58-	
1.91)	than	in	A1.





Non- DM T2DM T1DM Overall P- value
N 85 934 11	719 186 97	839
Age,	mean	(SD),	y 69.67	(11.2) 66.98	(10.2) 47.85	(13.7) 69.3	(11.2) <0.001
Male,	n	(%) 35	006	(40.7) 6271	(53.5) 106	(57.0) 41	383	(42.3) <0.001
Duration	of	diagnosed	diabetes,	
median	(IQR),	y
— 3.23	(0.8-	8.6) 20.64	(14.1-	30.7) 3.3	(0.8-	9.0) <0.001
Duration of diagnosed renal 
disease,	median	(IQR),	y
4.25	(2.2-	6.6) 4.72	(2.7-	7.0) 2.95	(0-	5.6) 4.3	(2.2-	6.6) <0.001
BMI,	mean	(SD),	kg/m2 27.48	(5.0) 30.04	(5.9) 25.88	(3.8) 28.1	(5.4) <0.001
Systolic	BP,	mean	(SD),	mm	Hg 148.27	(21.4) 146	(20.0) 138.95	(21.7) 147.9	(21.3) <0.001
Diastolic	BP,	mean	(SD),	mm	Hg 83.16	(11.6) 80.97	(10.8) 78.25	(11.8) 82.9	(11.6) <0.001
Smoking	status,	n	(%)
Never 48	261	(56.2) 6104	(52.1) 97	(52.2) 54	462	(55.7) <0.001
Ex-	smoker 23	211	(27.0) 3561	(30.4) 38	(20.4) 26	810	(27.4)
Current 13	782	(16.0) 2016	(17.2) 50	(26.9) 15	848	(16.2)
Missing 680	(0.8) 38	(0.3) 1	(0.5) 719	(0.7)
Alcohol	status,	n	(%)
Never 16	426	(19.1) 2904	(24.8) 27	(14.5) 19	357	(19.8) <0.001
Ex-	drinker 1619	(1.9) 353	(3.0) 6	(3.2) 1978	(2.0)
Current 62	316	(72.5) 7966	(68.0) 141	(75.8) 70	423	(72.0)
Missing 5573	(6.5) 496	(4.2) 12	(6.5) 6081	(6.2)
HbA1c,	median	(IQR),	% 5.7	(5.3-	6.0) 7.5	(6.6-	9.0) 9.0	(7.9-	10.5) 7.38	(6.4-	8.8) <0.001
HbA1c,	median	(IQR),	mmol/L 38.8	(34.4-	42.0) 58.5	(48.6-	74.9) 74.9	(62.3-	90.7) 57.19	(46.5-	72.7) <0.001
Serum	creatinine,	mean	(SD),	
μmol/L
105.0	(32.1) 101.1	(30.0) 117.5	(59.2) 104.55	(32.0) <0.001
GP	contacts	in	prior	year,	median	
(IQR)
5	(3-	9) 8	(4-	14) 7	(3-	12) 5	(3-	10) <0.001
Index	date	=	1st	positive	eGFR,	n	
(%)
85	727	(99.8) 11	036	(94.2) 151	(81.2) 96	914	(99.1) <0.001
eGFR	category	at	index	date,	n	(%)
G1 — — — — <0.001
G2 42	889	(50.0) 7043	(60.1) 101	(54.3) 50	033	(51.1)
G3a 30	359	(35.4) 2725	(23.3) 19	(10.2) 33	103	(33.8)
G3b 10	034	(11.7) 972	(8.3) 15	(8.1) 11	021	(11.3)
G4 2169	(2.5) 276	(2.4) 14	(7.5) 2459	(2.5)
G5 276	(0.3) 20	(0.2) 2	(1.1) 298	(0.3)
Index	date	=	1st	positive	
proteinuria,	n	(%)
253	(0.3) 844	(7.2) 38	(20.4) 1135	(1.2) <0.001
Proteinuria	status	at	index	date,	n	(%)
A1 — — — — <0.001
A2 63	(0.1) 505	(4.3) 15	(8.0) 583	(0.6)
A23 61	(0.1) 145	(1.2) 7	(3.8) 213	(0.2)
A3 129	(0.2) 194	(1.7) 16	(8.6) 339	(0.4)
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3.5 | Adjusted risk of progression to hospital 
admission by diabetes status
Adjusted	 models	 were	 run	 for	 the	 T2DM	 and	 non-	DM	 cohorts	
(Figure	2).	The	proposed	models	were	inappropriate	in	the	T1DM	co-
hort due to low numbers.
Within	the	T2DM	cohort,	there	was	no	significant	difference	be-
tween	 G1	 (aHR	=	1.00,	 0.80-	1.25)	 and	 G3a	 (aHR	=	1.03,	 0.92-	1.15)	









egories	 A2,	 A23	 and	A3	were	 all	 significant	 (Figure	2).	 There	was	
an association between worsening proteinuria and infection rates 
in	 categories	 A2	 (aHR	=	1.45,	 1.29-	1.63),	 A2/3	 (aHR	=	1.31,	 1.10-	
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TABLE  2 Rates of hospital admission with infection as the primary diagnosis
Non- DM T1DM T2DM
P- valueN
Crude event rate, 
pkpy N
Crude event rate, 
pkpy N
Crude event rate, 
pkpy
Patients 85 934 — 186 — 11	719 —
Patient	years 646	908 — 1459 — 95 935 —
Hospital	admissions
Any	listed	infection 16	101 24.9 35 24.0 3198 33.3 <0.001
Genitourinary 4707 7.3 7 4.8 1011 10.5 <0.001
Gastrointestinal 4440 6.9 3 2.1 604 6.3 <0.001
Pulmonary 4251 6.6 4 2.7 746 7.8 <0.001
Skin	and	soft	tissue 1902 2.9 17 11.6 567 5.9 <0.001
Sepsis 597 0.9 2 1.4 147 1.5 <0.001
Bone	and	joint 144 0.2 2 1.4 112 1.2 <0.001
Endocarditis 53 0.1 0 0 9 0.1 <0.001
Bacteremia 7 0.0 0 0 2 0.0 <0.001
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proteinuria,	were	both	associated	with	an	 increase	 in	 infection	rates,	
and that this association was independent. McDonald et al16 published 
a	study	similar	to	ours	that	 looked	at	the	associations	between	CKD	
and	the	 incidence	of	 infection	 in	patients	with	diabetes	aged	65	and	
older.	They	 found	 that	 there	was	an	association	between	eGFR	cat-
egory and rates of lower respiratory tract infection and sepsis. Their 
results have been validated in our study of a larger population of pa-
tients	aged	40	and	older	(25	and	older	for	those	with	type	1	diabetes)	
with and without diabetes.




events including ischaemic events and cardiac failure. The increasing 
burden of sepsis with worsening burden of renal impairment is rarely 
considered	by	clinicians.	As	potential	immunosuppressive	interventions	
for	CKD	emerge	that	may	reduce	the	fibrosis	associated	with	worsening	







with immunosuppressive therapy may therefore provide a favourable 
risk-	benefit	ratio	(G1-	G3a	in	type	2	diabetes;	G1-	G2	in	nondiabetes	and	
overall	cohorts),	although	further	studies	are	required	to	explore	this.
These data and the study design had a number of strengths and 






lieve that this will have introduced noise but not bias because there 
is	inherent	variability	in	the	monitoring	of	kidney	function	in	routine	
care.	 In	 identifying	 the	members	of	 our	 diabetes	 cohorts,	we	may	












turn have been incorrectly related to the infection outcome. This could 
be considered an additional limitation of the study.
Although	this	study	separately	analysed	the	effect	of	renal	impair-
ment	 and	 proteinuria	 on	 the	 risk	 of	 hospitalization	 for	 infection,	 an	





plained by the large proportion of missing data for proteinuria category.
In	 summary,	 it	has	already	been	established	 that	patients	with	
chronic	kidney	disease	(CKD),	particularly	ESRD,	have	an	increased	
incidence	 of	 infections,	 particularly	 those	 resulting	 in	 hospitaliza-
tions and death.13,27 There is also some evidence that patients with 
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with	and	without	diabetes,	and	validates	and	extends	previous	work	in	











analysis of the manuscript.
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